Clinical trials · Pennsylvania
Liver Fibrosis clinical trials in Pennsylvania
We’re tracking 6 recruiting liver fibrosis studies with a site in Pennsylvania — including Phase 1 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Pennsylvania
- NCT06632444RecruitingPhase 3
Study of survodutide for liver disease NASH/MASH with fibrosis
This trial tests an investigational drug called survodutide for people with NASH or MASH, a type of fatty liver disease that also has liver scarring (moderate or advanced fibrosis). The goal is to see if the drug can improve the condition.
Flourtown, PennsylvaniaAges 18 years+ - NCT05490888RecruitingPhase 1
Dose study of PHIN-214 for mild to moderate cirrhosis
This Phase 1 study tests how the medicine PHIN-214 behaves in the body and what dose is tolerable in people with Child-Pugh A or B liver cirrhosis. It may help doctors plan safer dosing for future studies.
Philadelphia, PennsylvaniaAges 18–75 - NCT06592820Recruiting
Ultrasound stiffness test for fatty liver disease
This study uses a special ultrasound technique, called shear wave elastography, to measure liver stiffness during an endoscopic ultrasound (EUS) procedure. It aims to see how well this new method detects liver scarring (fibrosis) in people with fatty liver disease, compared to standard tests like FibroScan and liver biopsy.
Danville, PennsylvaniaAges 18 years+ - NCT06165341RecruitingPhase 3
Fazirsiran for mild liver scarring in alpha-1 antitrypsin deficiency
This study tests an investigational drug called fazirsiran, which is designed to treat alpha-1 antitrypsin deficiency-related liver disease with mild scarring. The goal is to see if fazirsiran is safe and can improve or slow liver damage in people with the PiZZ genetic type.
Hershey, PennsylvaniaAges 18–75 - NCT05677971RecruitingPhase 3
Tested medicine to treat liver scarring in PiZZ alpha-1 disease
This Phase 3 study tests fazirsiran for safety and whether it can help people with a specific genetic form of alpha-1 antitrypsin–related liver disease that causes liver scarring. You may be eligible if you have the PiZZ genetic type and moderate-to-severe fibrosis, with certain lung and liver conditions ruled out.
Hershey, PennsylvaniaAges 18–75 - NCT06683092Recruiting
Restarting triple therapy with close monitoring for side effects
This trial tests whether carefully restarting a triple-combination CFTR modulator (VTD) is safe and helpful for people with cystic fibrosis who had to stop or change Trikafta because of mental health side effects or liver injury. You will be closely monitored with surveys and daily diaries to ensure your safety.
Pittsburgh, PennsylvaniaAges 6 years+
Where these studies are running in Pennsylvania
Institutions with a site for the recruiting liver fibrosis studies listed above.
- Penn State Milton S Hershey Medical Center · 3 studies
- Geisinger Medical Center
- Geisinger Medical Group
- Temple University Hospital
- University of Pennsylvania
- University of Pittsburgh Medical Center
- US Digestive Health
What taking part in a liver fibrosis study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Liver Fibrosis trials in other states
Common questions
- Are there liver fibrosis clinical trials in Pennsylvania?
- Yes. We're currently tracking 6 recruiting liver fibrosis studies with a site in Pennsylvania, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a liver fibrosis study in Pennsylvania?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Pennsylvania to take part?
- Not necessarily. These studies have a site in Pennsylvania, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a liver fibrosis trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New liver fibrosis studies open in Pennsylvania regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.